ZA200202060B - Use of CSAIDS in rhinovirus infection. - Google Patents
Use of CSAIDS in rhinovirus infection. Download PDFInfo
- Publication number
- ZA200202060B ZA200202060B ZA200202060A ZA200202060A ZA200202060B ZA 200202060 B ZA200202060 B ZA 200202060B ZA 200202060 A ZA200202060 A ZA 200202060A ZA 200202060 A ZA200202060 A ZA 200202060A ZA 200202060 B ZA200202060 B ZA 200202060B
- Authority
- ZA
- South Africa
- Prior art keywords
- inhibitor
- cbsp
- use according
- fluorophenyl
- therapeutic agent
- Prior art date
Links
- 206010061494 Rhinovirus infection Diseases 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 claims description 52
- 239000012826 P38 inhibitor Substances 0.000 claims description 51
- GHAFORRTMVIXHS-UHFFFAOYSA-L bromosulfophthalein sodium Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(O)=CC=C1C1(C=2C=C(C(O)=CC=2)S([O-])(=O)=O)C(C(Br)=C(Br)C(Br)=C2Br)=C2C(=O)O1 GHAFORRTMVIXHS-UHFFFAOYSA-L 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 28
- 241000700605 Viruses Species 0.000 claims description 27
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 claims description 24
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 claims description 24
- 229940124597 therapeutic agent Drugs 0.000 claims description 22
- 241000709661 Enterovirus Species 0.000 claims description 21
- 241000430519 Human rhinovirus sp. Species 0.000 claims description 20
- 206010022000 influenza Diseases 0.000 claims description 20
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims description 19
- -1 rimantidine Chemical compound 0.000 claims description 17
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 14
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 206010035664 Pneumonia Diseases 0.000 claims description 9
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 9
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 8
- 239000003443 antiviral agent Substances 0.000 claims description 8
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 8
- 229960003752 oseltamivir Drugs 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 7
- 206010033078 Otitis media Diseases 0.000 claims description 7
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 7
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 7
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 7
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 7
- 229960003805 amantadine Drugs 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 230000001387 anti-histamine Effects 0.000 claims description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 7
- 239000000739 antihistaminic agent Substances 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 229940111134 coxibs Drugs 0.000 claims description 7
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 7
- 239000000850 decongestant Substances 0.000 claims description 7
- CAYJBRBGZBCZKO-BHGBQCOSSA-N ethyl (e,4s)-4-[[(2r,5s)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-4-oxoheptanoyl]amino]-5-[(3s)-2-oxopyrrolidin-3-yl]pent-2-enoate Chemical compound C([C@@H](/C=C/C(=O)OCC)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)C1=NOC(C)=C1)C(C)C)CC=1C=CC(F)=CC=1)[C@@H]1CCNC1=O CAYJBRBGZBCZKO-BHGBQCOSSA-N 0.000 claims description 7
- 229960000905 indomethacin Drugs 0.000 claims description 7
- 201000009240 nasopharyngitis Diseases 0.000 claims description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 7
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 claims description 7
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 7
- 229960001084 peramivir Drugs 0.000 claims description 7
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 claims description 7
- 229960000471 pleconaril Drugs 0.000 claims description 7
- 229940061374 relenza Drugs 0.000 claims description 7
- 229960000329 ribavirin Drugs 0.000 claims description 7
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 7
- 239000002911 sialidase inhibitor Substances 0.000 claims description 7
- 201000009890 sinusitis Diseases 0.000 claims description 7
- 150000003431 steroids Chemical class 0.000 claims description 7
- 229940061367 tamiflu Drugs 0.000 claims description 7
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 7
- 241000711573 Coronaviridae Species 0.000 claims description 6
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims description 6
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 claims description 6
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims description 6
- LNKHWGSSSPTTHB-CJLVFECKSA-N (e)-n-ethoxy-1-[4-[2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy]phenyl]methanimine Chemical compound C1=CC(/C=N/OCC)=CC=C1OCCC1CCN(C=2N=NC(C)=CC=2)CC1 LNKHWGSSSPTTHB-CJLVFECKSA-N 0.000 claims description 5
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 208000007451 chronic bronchitis Diseases 0.000 claims description 5
- 150000002460 imidazoles Chemical class 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- ZNFJBJDODKHWED-QGOAFFKASA-N 4-[4-[(e)-(2-oxo-1h-indol-3-ylidene)methyl]phenyl]piperazine-1-carbaldehyde Chemical compound C1CN(C=O)CCN1C(C=C1)=CC=C1\C=C\1C2=CC=CC=C2NC/1=O ZNFJBJDODKHWED-QGOAFFKASA-N 0.000 claims description 3
- PDTYLGXVBIWRIM-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCNCC2)=N1 PDTYLGXVBIWRIM-UHFFFAOYSA-N 0.000 claims description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- ZDKIAVFEUPUCMR-UHFFFAOYSA-N 2-[4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl)imidazol-1-yl]propane-1,3-diol Chemical compound OCC(CO)N1C=NC(C=2C=CC(F)=CC=2)=C1C(N=1)=CC=NC=1OC1=CC=CC=C1 ZDKIAVFEUPUCMR-UHFFFAOYSA-N 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims 6
- PYEFPDQFAZNXLI-UHFFFAOYSA-N 3-(dimethylamino)-N-[3-[[(4-hydroxyphenyl)-oxomethyl]amino]-4-methylphenyl]benzamide Chemical compound CN(C)C1=CC=CC(C(=O)NC=2C=C(NC(=O)C=3C=CC(O)=CC=3)C(C)=CC=2)=C1 PYEFPDQFAZNXLI-UHFFFAOYSA-N 0.000 claims 2
- ZQUSFAUAYSEREK-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1-imidazolyl]-1-cyclohexanol Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCC(O)CC2)=N1 ZQUSFAUAYSEREK-UHFFFAOYSA-N 0.000 claims 2
- HYXPWOSDWIYCSH-QRIJWHNFSA-N chembl308003 Chemical compound CS(O)(=O)=O.N1C([C@H]2OC[C@](CO2)(C)C(=O)N2CCOCC2)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 HYXPWOSDWIYCSH-QRIJWHNFSA-N 0.000 claims 2
- ADQZGIYHFQQPRB-UHFFFAOYSA-N 2-(4-fluorophenyl)-4-methoxy-3-pyridin-4-yl-1h-pyrrolo[2,3-b]pyridin-6-amine Chemical compound C1=2C(OC)=CC(N)=NC=2NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 ADQZGIYHFQQPRB-UHFFFAOYSA-N 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 38
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 38
- 125000000217 alkyl group Chemical group 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 28
- 208000015181 infectious disease Diseases 0.000 description 25
- 238000011282 treatment Methods 0.000 description 21
- 102000004127 Cytokines Human genes 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 19
- 125000000623 heterocyclic group Chemical group 0.000 description 16
- 108090001005 Interleukin-6 Proteins 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- 125000003118 aryl group Chemical group 0.000 description 13
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 108090001007 Interleukin-8 Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 241000712461 unidentified influenza virus Species 0.000 description 11
- 230000009385 viral infection Effects 0.000 description 10
- 108010002352 Interleukin-1 Proteins 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 125000001570 methylene group Chemical class [H]C([H])([*:1])[*:2] 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- CDMGBJANTYXAIV-UHFFFAOYSA-N SB 203580 Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 CDMGBJANTYXAIV-UHFFFAOYSA-N 0.000 description 7
- 150000002431 hydrogen Chemical group 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 229940043355 kinase inhibitor Drugs 0.000 description 7
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 7
- 230000009325 pulmonary function Effects 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 125000003107 substituted aryl group Chemical group 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 102000003896 Myeloperoxidases Human genes 0.000 description 5
- 108090000235 Myeloperoxidases Proteins 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000021995 interleukin-8 production Effects 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000011593 sulfur Chemical group 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 4
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 3
- UXTIAFYTYOEQHV-UHFFFAOYSA-N 4-(4-amino-3-methoxyphenyl)-2-methoxyaniline;hydron;dichloride Chemical compound [Cl-].[Cl-].C1=C([NH3+])C(OC)=CC(C=2C=C(OC)C([NH3+])=CC=2)=C1 UXTIAFYTYOEQHV-UHFFFAOYSA-N 0.000 description 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Chemical group 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 229960001271 desloratadine Drugs 0.000 description 3
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010009137 Chronic sinusitis Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102100037268 Secretoglobin family 3A member 1 Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 208000024035 chronic otitis media Diseases 0.000 description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 229960003592 fexofenadine Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229960003088 loratadine Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007302 negative regulation of cytokine production Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000037874 Asthma exacerbation Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 101000932768 Conus catus Alpha-conotoxin CIC Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101100295738 Gallus gallus COR3 gene Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100030385 Granzyme B Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101100533874 Hypocrea jecorina (strain QM6a) sor5 gene Proteins 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- JMQMNWIBUCGUDO-UHFFFAOYSA-N L-Djenkolic acid Natural products OC(=O)C(N)CSCSCC(N)C(O)=O JMQMNWIBUCGUDO-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- JMQMNWIBUCGUDO-WHFBIAKZSA-N L-djenkolic acid Chemical compound OC(=O)[C@@H](N)CSCSC[C@H](N)C(O)=O JMQMNWIBUCGUDO-WHFBIAKZSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- CYZKJBZEIFWZSR-LURJTMIESA-N N(alpha)-methyl-L-histidine Chemical compound CN[C@H](C(O)=O)CC1=CNC=N1 CYZKJBZEIFWZSR-LURJTMIESA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229940008201 allegra Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940088007 benadryl Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 229940036139 zyrtec Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Use of CSAIDs in Rhinovirus infection
The present invention relates to the use of a CSBP/p38 inhibitor in the treatment of a
CSBP/p38 mediated disease.
Human rhinovirus (HRV), the most frequent cause of the common cold, is increasingly associated with more serious sequelae including exacerbation's of asthma, chronic bronchitis, COPD, otitis media, and sinusitis (Gern et al., Clin
Micro Reviews 12(1): 9-18 (1999); Pitkaranta, and Hayden, Annals of Medicine 30 (6): 529-537 (1998); Seermungal et al, ATS abstract "Rhinoviruses are associated with exacerbation's of COPD" (1998)). Recent published studies in adults and adolescents, using PCR to assist in viral detection, have shown that up to 50 to 80% of asthma exacerbation's are associated with upper respiratory tract virus infection, and that rhinovirus is the most common virus (d#mar ef al, Archives of Internal
Medicine. 158 (22): 2453-9 (1998), .Johnston, SL., British Medical Journal 310: 1225-9 (1995)). HRV infects nasal epithelial cells; recent evidence suggests the virus may also infect bronchial epithelium. Prodromal cold symptoms are apparent within 24 hours post-infection, peak on days 2 through 5, and resolve within seven to fourteen days; but can be more protracted in some individuals. Symptoms are believed to arise more from the host's response to infection, than an acute cytotoxic effect, since only a small fraction of upper respiratory epithelial cells are demonstrably infected, and there is minimal epithelial cell damage (Winther et al,
JAMA 256: 1763-1767 (1986). Increased intranasal levels of kinins, IL-1, IL-8, IL- 6, IL-11, and neutrophils are found in normal individuals infected with rhinoviruses.
A correlation between IL-8 concentration in nasal secretions with local myeloperoxidase levels and with symptom severity has been demonstrated in several recent studies (Grieff, et al. Eur Respir I 13: 41-47 (1999); Teren, et al. Am J Respir
Crit Care Med 155: 1362-1366 (1997), Turner, et al. Clin Infect Dis 26; 840-846 (1998). Intranasal concentrations of IL-1 and IL-6 have been correlated with symptom severity as well (Proud ef al, J. Infect. Dis.169:1007-1013 (1/994); Zhu et al, J. Clin. Invest. 97:421-430 (/996)). Experimental rhinovirus infection also results in enhanced immediate and late phase allergic reactions, and in increased infiltration of T lymphocytes and eosinophils into the lower airways. In atopics and x. Le, asthmatics, these effects persist for up to 2 months post - infection (Gern and Busse, ) Am J Respir Crit Care Med, 152: S40-S45 (7995). Human bronchial epithelial cell lines have been shown to produce IL-1, IL-6, IL-8, IL-11 and GM-CSF in response . to rhinovirus infection (Subauste et al, J Clin Invest, 96: 549-557 (1995); Gern et
S al, supra, 1999). Early production of cytokines by rhinovirus - infected epithelial cells may therefore be responsible for triggering recruitment of neutrophils, T cells and activated eosinophils into the upper and lower airways.
In addition, IL-1, IL-6, and IL-8 are also produced in response to infection with other respiratory viruses (influenza, respiratory syncytial virus) which can cause the common cold and associated sequelae.
By interfering with the biochemical processes of epithelial cells resulting from virus infection there represents a viable new therapeutic target by an inhibitor of CSBP/p38. This invention is directed to the novel discovery of treatment of this therapeutic target.
The present invention relates to the use of a CSBP/p38 kinase inhibitor for the treatment, including prophylaxis, of the common cold, or respiratory viral infection caused by human rhinovirus infection (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or adenovirus infection in a human in need thereof which method comprises administering to said human an effective amount of a CBSP/p38 inhibitor.
Another aspect of the present invention is a method of treating, including prophylaxis of influenza induced pneumonia in a human in need thereof which method comprises administering to said human an effective amount of a CBSP/p38 inhibitor
The present invention also relates to the use of the CSBP/p38 kinase inhibitor for the treatment, including prophylaxis, of inflammation associated with a viral infection of a human rhinovirus (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or adenovirus.
Figure 1 demonstrates Cytokine Production by Rhinovirus infected BEAS- 2B cells. Culture supernatants were collected 72 hours post-infection of BEAS-2B cells with rhinovirus-39 (MOI 1). Uninfected cells served as controls. Protein concentrations in supernatants were determined by ELISA (R&D Systems). Results represent the mean concentration values obtained from 6 experiments.
Figure 2 demonstrates Inhibition of cytokines by CSAIDs: BEAS-2B cultures infected with rhinovirus-39 were cultured in the presence of various : concentrations of drug. Cytokine levels in supernatant were determined 72 hours post-infection using commercially available ELISA kits. Results are expressed as % } inhibition from infected untreated cultures. Cytokine concentrations in infected control cultures were 4902 pg/ml IL-6, 4520 pg/ml IL-8, and 28 pg/ml GM-CSF.
Figure 3 demonstrates Tyrosine phosphorylation of p38 kinase by rhinovirus infection. BEAS-2B cells were incubated with rhinovirus-39 for various times as indicated. Cell lysates were separated by 10% SDS-polyacrylamide gel, transferred to nitrocellulose membrane and probed with specific antibody to phosphorylated p38 kinase (A) or total p38 kinase (B). Amounts of p38 kinase were quantitated by image analyzer and are presented as volumes based on densitometer scans.
Figure 4 demonstrates Tyrosine phosphorylation of p38 kinase by rhinovirus infection. BEAS-2B cells were incubated with various doses (MOI) of rhinovirus- 39 for 30 minutes. Cell lysates were separated by 10% SDS-polyacrylamide gel, transferred to nitrocellulose membrane and probed with specific antibody to phosphorylated p38 kinase or total p38 kinase. Amounts of p38 kinase were quantitated by image analyzer and are presented as relative amounts of total or phosphorylated p38 kinase compared to control cells incubated with media alone (fold increase).
Figure 5 demonstrates the effect of Compound VI, 1-(1,3-Dihydroxyprop-2- yl)-4-(4-fluorophenyl)-5-[2-phenoxypyrimidin-4-yl Jimidazole on improvement of pulmonary function with increasing doses. BALB/c mice were treated from days 3-8 post-infection with a sub-lethal dose of Influenza A. Pulmonary resistance was determined using whole body plethysmography.
Figure 6 demonstrates the effect of Compounds V, 1-(4-Piperidinyl)-4-(4- fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)imidazole and Compound VI, on prevention of weight loss in animals in an in vivo influenza model.
Figure 7 demonstrates the efficacy of of Compounds V and VI at improving arterial blood oxygen levels (%SpO2) upon treatment. SpO2 was determined using daily pulse oximetry.
IL-1, TNF, and other cytokines affect a wide variety of cells and tissues and these cytokines as well as other leukocyte derived cytokines are important and critical inflammatory mediators of a wide variety of disease states and conditions.
DE WO 01/19322 PCT/US00/25386
The inhibition of these cytokines is of benefit in controlling, reducing and alleviating . many of these disease states.
In particular, the present invention is directed to the treatment of a viral ] infection in a human, which is caused by the human rhinovirus (HRV), other 5S enterovirus, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or an adenovirus. In particular the invention is directed to respiratory viral infections that exacerbate asthma (induced by such infections), chronic bronchitis, chronic obstructive pulmonary disease, otitis media, and sinusitis. While inhibiting
IL-8 or other cytokines may be beneficial in treating a rhinovirus may be known, the use of an inhibitor of the p38 kinase for treating HRV or other respiratory viral infections causing the common cold is believed novel.
It should be noted that the respiratory viral infection treated herein may also be associated with a secondary bacterial infection, such as otitis media, sinusitis, or pneumonia.
For use herein treatment may include prophylaxis for use in a treatment group susceptible to such infections. It may also include reducing the symptoms of] ameliorating the symptoms of, reducing the severity of, reducing the incidence of, or any other change in the condition of the patient, which improves the therapeutic outcome.
The mechanism of action for inhibition of a cytokine by a cytokine suppressive anti-inflammatory drug (CS AID) versus inhibition of virus - induced
IL-8 production in airway epithelial cells is believed to be different. In the rhinovirus system, IL-8 production, and CSAID inhibition of IL-8 synthesis is independent of IL-1 and TNF production, whereas the published studies have focused on IL-1 and TNF - induced IL-8 production.
It should be noted that the treatment herein is not directed to the elimination or treatment of the viral organism itself but is directed to treatment of the respiratory viral infection that exacerbates other diseases or symptoms of disease, such as asthma (induced by such infections), chronic bronchitis, chronic obstructive pulmonary disease, otitis media, and sinusitis.
The present invention will demonstrate that CSAID inhibitors are useful in the treatment of symptoms associated with HRV, including exacerbations of underlying conditions such as asthma, COPD, sinusitis and otitis media amongst others.
A preferred virus for treatment herein is the human rhinovirus infection (HRV) or respiratory syncytial virus (RSV).
Another aspect of the present invention is a method of treating, including prophylaxis of influenza induced pneumonia in a human in need thereof which . method comprises administering to said human an effective amount of a CBSP/p38 inhibitor. Therefore, for this usage, a preferred virus for treatment is the influenza virus. oo N
Lastly, another aspect of the present invention relates to the use of a
CSBP/p38 kinase inhibitor for the treatment, including prophylaxis, of inflammation associated with a viral infection of a human rhinovirus (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or adenovirus. Preferably the viral infection is HRV or RSV, or the influenza or parainfluenza virus.
Suitable CSAID compounds are well known in the art, and an assay for determining CBSP/p38 inhibition is also readily available using assays disclosed in the below noted patents or applications. For instance, see US Patents 5,716,972, US 5,686,455, US 5,656,644, US 5,593,992, US 5,593,991, US 5,663,334, US 5,670,527, US 5,559,137, 5,658,903, US 5,739,143, US 5,756,499, and US 5,716,955; WIPO publications WO 98/25619, WO 97/25048, WO 99/01452, WO 97/25047, WO 99/01131, WO 99/01130, WO 97/33883, WO 97/35856, WO 97/35855, WO 98/06715, WO 98/07425, WO 98/28292, WO 98/56377 , WO 98/07966 , WO 99/01136 , WO 99/17776 , WO 99/01131 , WO 99/01130, WO 99/32121, WO 00/26209, WO 99/58502, WO 99/58523, WO 99/57101, WO 99/61426, WO 99/59960, WO 99/59959, WO 00/18738, WO 00/17175, WO 99/17204, WO 00/20402, WO 99/64400, WO 00/01688, WO 00/07980, WO 00/07991, WO 00/06563, WO 00/12074, WO 00/12497, WO 00/31072, WO 00/31063, WO 00/23072, WO 00/31065, WO 00/35911, WO 00/39116, WO 00/43384, WO 00/41698, WO 97/36587, WO 97/47618, WO 97/16442, WO 97/16441, WO 97/12876, WO 98/7966, WO 98/56377, WO 98/22109, WO 98/24782, WO 98/24780, WO 98/22457, WO 98/52558, WO 98/52941, WO 98/52937, WO 98/52940, WO 98/56788, WO 98/27098 , WO 99/00357, WO 98/47892, WO 98/47899, WO 99/03837, WO 99/01441, WO 99/01449, WO 99/03484, WO 95/09853, WO 99/15164, WO 98/50356; WO 95/09851, WO 95/09847, WO 95/09852, WO 92/12154, WO 94/19350, DE 19842833, JP 2000 86657 and De Laszlo et al., Bioorg. Med. Chem. Lett 8 (1998) 2689-2694 whose disclosures are all incorporated herein by reference in their entirety.
Preferred compounds of this invention include those contained in WO 99/01131, and a representative genus is described below. Also preferred for use herein are the compounds disclosed in WO 99/61426 Scios, Inc.; and those compounds disclosed in WO 98/27098 containing the compound known as VX-745; 40 (also known as 5-(2,6-Dichloro-phenyl)-2-(2,4-difluoro-phenylsulfanyl)-1,7,8a-
] = WO 01/19322 PCT/US00/25386 triaza-naphthalen-6-one), the Johnson & Johnson compound RWJ-683 54 disclosed in disclosed in WO 99/15164; the Sugen compound SU 4984 disclosed in WO 98/50356. A review of various inhibitors of p38 kinase is taught in Boehm et al,
Exp. Opin. Ther. Patents 10(1):25-37 (2000). BN
Compounds of Formula (1) are represented by the formula:
R; fr pi
RN wherein
R1 is 4-pyridyl, pyrimidinyl, 4-pyridazinyl, 1,2 4-triazin-5-yl, quinolyl, isoquinolinyl, or quinazolin-4-yl ring, which ring is substituted with Y-Rg and optionally with an additional independent substituent selected from C]-4 alkyl, halogen, hydroxyl, C1-4 alkoxy, C1-4 alkylthio, C]-4 alkylsulfinyl, CH2OR 2, amino, mono and di- C1-¢ alkyl substituted amino, an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR15, N(R10)C(O)Rp or NHRg;
Y is oxygen or sulfur;
R4 is phenyl, naphth-1-yl or naphth-2-yl, or a heteroaryl, which is optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-1-yl, 5-naphth-2-yl or 6-naphth-2-yl substituent, is halogen, cyano, nitro, C(Z)NR7R 17, C(Z)OR]s6, (CR10R20)vCOR12, SR5, SORS5, OR]2, halo-substituted-C]-4 alkyl, Cj-4 alkyl, ZC(Z)R12, NR10C(Z)R16, or (CR10R20)vNR10R20 and which, for other positions of substitution, is halogen, cyano, C(Z)NR13R14, C(Z)OR3, (CR10R20)m"COR3, S(O)mR3, OR3, halo-substituted-C]-4 alkyl, C1-4 alkyl, (CR10R20)m"NR10C(Z)R3, NR10S(O)mR8, NR10S(0)m'NR7R17, ZC(Z)R3 or (CR10R20)m"NR13R 14;
Z is oxygen or sulfur; nis an integer having a value of 1 to 10; m is 0, or the integer 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5;
v 1s 0, or an integer having a value of 1 or 2;
R2 is -C(H) (A) R22); :
A is an optionally substituted aryl, heterocyclyl, or heteroaryl ring, or A is a substituted
C1-10 alkyl; Rpj is an optionally substituted Cy_1¢ alkyl,
Ra is aryl, arylCj-galkyl, heterocyclic, heterocyclylC1-6 alkyl, heteroaryl, heteroarylCj-galkyl, wherein each of these moieties may be optionally substituted;
Rb is hydrogen, C1-6 alkyl, C3.7 cycloalkyl, aryl, arylC]-4 alkyl, heteroaryl, heteroarylC]-4alkyl, heterocyclyl, or heterocyclylC]-4 alkyl, wherein each of these moieties may be optionally substituted;
R3 is heterocyclyl, heterocyclylC1-10 alkyl or Rg;
Rs is hydrogen, C1-4 alkyl, C2-4 alkenyl, C24 alkynyl or NR7R]7, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH;
Rg is hydrogen, a pharmaceutically acceptable cation, C1-10 alkyl, C3.7 cycloalkyl, aryl, arylC1-4 alkyl, heteroaryl, heteroarylC-4alkyl, heterocyclyl, aroyl, or
C1-10 alkanoyl;
R7 and R17 is each independently selected from hydrogen or C14 alkyl or R7 and
R17 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15;
Rg is C1-10 alkyl, halo-substituted C]-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C37 cycloalkyl, C5.7 cycloalkenyl, aryl, arylC1-10 alkyl, heteroaryl, heteroarylCj.10 alkyl, (CR10R20)nOR11, (CR10R20)nS(O)mR18, (CR10R20)nNHS(O)2R18, (CR10R20)nNR13R 14; wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl may be optionally substituted;
Ro is hydrogen, C(Z)R11] or optionally substituted C]-10 alkyl, S(O)2R18, optionally substituted aryl or optionally substituted aryl-C1-4 alkyl;
R10 and R20 is each independently selected from hydrogen or C1.4 alkyl;
Rji is hydrogen, C1-10 alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl
C1-10alkyl, aryl, arylC1-10 alkyl, heteroaryl or heteroarylCj-10 alkyl, wherein these moieties may be optionally substituted;
R]2 is hydrogen or Rig;
R13 and R14 is each independently selected from hydrogen or optionally substituted
C1-4 alkyl, optionally substituted aryl or optionally substituted aryl-C1-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of
Co WO 01/19322 PCT/US00/25386 to 7 members which ring optionally contains an additional heteroatom selected . from oxygen, sulfur or NRg
R15 1s R10 or C(Z)-C1-4 alkyl;
R16 is C1-4 alkyl, halo-substituted-C1-4 alkyl, or C3.7 cycloalkyl; 5 Rigs C1-10 alkyl, C3-7 cycloalkyl, heterocyclyl, aryl, aryl]-10alkyl, heterocyclyl, heterocyclyl-C1-10alkyl, heteroaryl or heteroaryl]-10alkyl; or a pharmaceutically acceptable salt thereof.
Rs is a substituted alkyl derivative. It is recognized that the first methylene carbon in this chain is a tertiary carbon, and it will contain one hydrogen moiety. This methylene group will have has two additional substituents, an Rp» moiety and an A moiety, -C(H)(A)(Rp2). Both A and Ry» may not be unsubstituted Cj._1¢ alkyl moieties.
In a preferred embodiment, R2 is a -C(AA1)(A) moiety, wherein AA] is the
Rp, moiety, but 1s specifically the side chain residue (R) of an amino acid, as is further described herein.
Suitably, A is an optionally substituted C3-7cycloalkyl, aryl, heteroaryl, or heterocyclic ring, or A is a substituted C_jq alkyl moiety.
When A is an aryl, heteroaryl and heterocyclic ring, the ring may be substituted independently one or more times, preferably, 1 to 3 times by C1-10 alkyl; halogen; halo substituted C1-10 alkyl, such as CF3; (CR10R20)}tOR11; (CR10R20)tNR13R14, especially amino or mono- or di-Cy_4 alkylamino; (CR10R20)tS(O)mR18, wherein m is 0, 1 or 2; SH; NR10C(Z)R3 (such NHCO(C1-10 alkyl)); or NR10S(O)mR8 (such as
NHSO2(C1-10 alkyl).
Suitably, t is 0, or an integer of 1 to 4.
When A is an optionally substituted cycloalkyl it is as defined below with the
Ry7 substitution.
When A is an optionally substituted heterocyclyl ring, the ring is preferably a morpholino, pyrrolidinyl, piperaziny! or a piperidinyl ring.
When A is an optionally substituted aryl moiety, it is preferably a phenyl ring.
When A is an optionally substituted heteroaryl ring, it is as defined below in the definition section.
When A is a substituted Cj_1g alkyl moiety, the alkyl chain may be straight or branched. The chain is substituted independently 1 or more times, preferably 1 to 3 times by halogen, such as fluorine, chlorine, bromine or iodine; halosubstituted C1-1¢0 alkyl, such as CF3; C3.7cycloalkyl, C1-10 alkoxy, such as methoxy or ethoxy; hydroxy substituted C1-10 alkoxy; halosubstituted Cj.10 alkoxy, such as OCF,CF3H;
OR]; S(O)mR1g (wherein mis 0, 1 or 2); NR13R14; C(Z)NR13R 14;
S(0)mNR13R14; NR23C(Z)R11; NHS(0)2R18; C(Z)R11; OC(Z)R11; C(Z)OR]1;
C(Z)NR110R9; N(OR6)C(Z)NR13R14; N(OR6)C(Z)R11; C(=NOR6)R]1;
NR23C(=NR]9)NR13R14; OC(Z)NR13R14; NR23C(Z)NR13R14; or
NR23C(Z)ORjpp.
Preferably A is a C3_7 cycloalkyl, or a Cj_g alkyl, more preferably a Cy» alkyl, i.e. a methylene or ethylene moiety, more preferably a methylene moiety which is substituted by one of the above noted groups.
Preferably, when A is a C1_j alkyl, it is substituted by OR] where Ryjis preferably hydrogen, aryl or arylalkyl; NR13R14; OC(Z)R11; or C(Z)OR] 1.
More preferably, A is substituted by OR where Rj is hydrogen.
Suitably, Rp is a Cj_1( alkyl chain, which chain may be straight or branched and which may be optionally substituted independently, one or more times, preferably 1 to 3 times, by halogen, such as fluorine, chlorine, bromine or iodine; halo substituted
C1-10 alkyl; C1-10 alkoxy, such as methoxy or ethoxy; hydroxy substituted C110 alkoxy; halosubstituted C]-10 alkoxy, such as OCF 2CF7H; OR]1; S(O)mR18;
NR13R14; C(Z)NR13R14; S(O)mNR13R14; NR23C(Z)R]1; NHS(O)2R18;
C(Z)R11; OC(Z)R11; C(Z)OR11; C(Z)NR]110R9; N(OR6)C(Z)NR13R 14;
N(OR6)C(Z)R11; C(=NOR6)R11; NR23C(=NR19)NR13R14; OC(Z)NR]3R14;
NR23C(Z)NR1]3R14; NR23C(Z)OR]0; optionally substituted C3._7 cycloalkyl; optionally substituted aryl, such as phenyl; optionally substituted heteroaryl; or an optionally substituted heterocyclic. The optional substituents on these cycloalkyl, aryl, heteroaryl, and heterocyclic moieties are as defined herein below.
It is noted that those Ryo substituent groups which contain carbon as the first connecting group, i.e. C(Z)OR]1; C(Z)NR] 10Rg C(Z)R11, C(Z)NR13R14, and
C(=NORg)R| 1, may be the sole carbon in alkyl chain. Therefore, the R97 group may, for instance, be a carboxy, an aldehyde, or an amide, as well as being a substituent off a methylene unit, such as carbamoylmethyl, or acetamidomethyl.
Preferably Rp; is a C1_g unsubstituted or substituted alkyl group, such as a C13 alkylene, such as methyl, ethyl or isopropyl, or a methylene or ethylene moiety substituted by one of the above noted moieties, or as noted above those substituent groups which contain a carbon may substitutent for the first methylene unit of the alkyl chain, such as carboxy, C(O)OR], C(O)NR{3R|4, or Ry is an optionally substituted aryl group, such as a benzyl or phenethyl. In other words, R22 can be an optionally substituted alkyl group, or Ry can be C(Z)OR]], C(Z)NR] 10R9, C(Z)R11,
C(Z)NR13R14, or C(=NORg)R 11.
ot WO 01/19322 PCT/US00/25386
Preferably Rpg is a Cj.g unsubstituted or substituted alkyl group, more . preferably a Cj _5 alkylene chain, such as a methylene or ethylene moiety, more preferably methylene.
Preferably the alkyl chain is substituted by OR}, where Ry is preferably hydrogen, aryl or arylalkyl; S(O)mRg, where mis 0 and Ryg is a Cj_g alkyl; or an optionally substituted aryl, i.e. a benzyl or phenethyl moiety.
More preferably, R72 is phenyl, benzyl, CHpOH, or CH;-O-aryl.
Preferably, one or both of A and R55 contain hydroxy moieties, such as in C1_g alkyl OR], wherein R11 is hydrogen, i.e. CHyCH,OH.
Suitably, when AAj is the (R) side chain residue of an amino acid, itisa C1_g alkyl group, which may be straight or branched. This means the R group off the core amino acid of the structure R-C(H)(COOH)(NHj3). The R residue term is for example,
CH3 for alanine, (CH3)2CH- for valine, (CH3)7CH-CHj-for leucine, phenyl-CH,- for phenylalanine, CH3-S-CH,-CHj- for methionine, etc. All generally recognized primary amino acids are included in this groups, such as but not limited to, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, hydroxylysine, methylhistidine, and other naturally occurring amino acids not found in proteins, such as -alanine, y-aminobutyric acid, homocysteine, homoserine, citrulline, ornithine, canavanine, djenkolic acid, and B- cyanoalanine, or other naturally occurring non-mammalian amino acids.
Preferably AA is the residue of phenylalanine, or alanine.
Preferably, A is a hydroxy substituted Cy_1g alkyl, and Ryp isa Cq.jg alkyl or a hydroxy substituted C1.1¢ alkyl.
For further definitions please refer to the descriptions in WO 99/01131, orin
WO 99/01136, supra.
A preferred compound for use of 1-(1,3-Dihydroxyprop-2-yl)-4-(4- fluorophenyl)-5-(2-phenoxypyrimidin-4-yl)imidazole, or a pharmaceutically acceptable salt thereof.
Other suitable compounds for use herein include but are not limited to, trans- 1-(4-Hydroxycyclohexy!)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4- yllimidazole; 1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinyl)imidazole; or (4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4- pyridyl)-imidazole.
Methods of using and dosage amounts are the same as those disclosed in the references cited above. See for instance, Adams et al., US patent 5,756,499, issued 26 May 1998. In order to use a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. .
For all methods of use disclosed herein (or the compounds of Formula (I) and other CSAID compounds), suitably, the daily oral dosage regimen will be from 5S about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to 30 mg/kg, more preferably from about 0.5 mg to 15mg. The daily parenteral dosage regimen about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to about 30 mg/kg, and more preferably from about 0.5 mg to 15mg/kg. The daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily. The daily inhalation dosage regimen will preferably be from about 0.01 mg/kg to about 1 mg/kg per day.
The novel use of CSAID compounds herein may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of CSBP/p38 or cytokine inhibition or production for treatment of influenza pneumonia, and other sequelae associated with viral infection.
The CSBP/p38 inhibitor may also be administered with a second therapeutic agent. The second therapeutic agent may be an antiviral agent such as ribavirin, amantidine, rimantidine, Pleconaril, AG 7088 or BTA-188; it may also be an antiviral agent such as an influenza neuraminidase inhibitor, such as zamanivar (Relenza), oseltamivir (Tamiflu) or RWJ-270201; it may be an antihistamine, such as Benadryl®, chlorpheneramine and salts thereof, brompheneramine or salts thereof, and the generally accepted non-sedating antihistamines, such as loratadine (Claritin®), descarboethoxyloratadine (DCL), fexofenadine (Allegra®), and cetirizine hydrochloride (Zyrtec®) etc., a decongestant, such as phenylpropanolamine and salts thereof, pseudoephedreine or salts thereof: steroids, such as dexamethasone, prednisone, or prenisolone, etc.; various antibiotics, such as the quinolones, cephalosporins, B-lactamase inhibitors, etc.; anti-inflammatory agents, such as an NSAID, a COX-1 or COX-2 inhibitor, ASA, or indomethacin, etc. Itis recognized that the above noted agents may be administerd as immediate release, or as extended release dosage forms, either together with a suitable CSAID compound, or seperately. The compositions may be administered sequentially, in combination with, or contemporaneously with a CSAID agent. The administration route of the second agent may also differ from that of the CSAID agent, and hence the dosing schedule may vary accordingly.
Cetirizine HCl manufacture and dosing is described in US Patent 4,525,358; fexofenadine manufacture and dosing is described in US Patents 4,524,129; US 5,375,693; US 5,578,610; US 5,855,912; US 5,932,247; and US 6,037,353.
Ce WO 01/19322 PCT/US00/25386
Loratadine and DCL manufacture and dosing are described in US patent 4,282 233; : US 4,371,516; US 4,659,716; US 4,863,931; US 5,314,697; and US 5,595,997.
Zamanivar dosing is disclosed in US Patents 4,627,432; US 4,778,054; US 4,811,731; US 5,035,237; US 5,360,817; and US 5,648,379. Oseltamivir dosing is disclosed in US Patents US 5,763,483; US 5,866,601; and US 5,952,375.
The CSPB/p38 inhibitor may be administered systemically or non- systemically, such as orally, bucally, topically (intranasal) or via inhalation (aerosol), or both topically and via inhalation. As noted above, the second therapeutic agent may be administered by any suitable means, including parenteral, suppository, etc. which means of administration is not necessarily by the same route, nor concurrent therewith.
As used herein "topically" shall include non-systemic administration. This includes the application of a compound externally to the epidermis or the buccal cavity and/or the instillation of such a compound into the ear, eye and nose.
As used herein "systemic administration" refers to oral, intravenous, intraperitoneal and intramuscular administration, subcutaneous intranasal, intrarectal, or intravaginal.
It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a CSBP/p38 inhibitor will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a
CSBP/p38 inhibitor given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
Methods:
Cell lines, rhinovirus serotype 39, and influenza virus A/PR/8/34 were purchased from American Type Culture Collection (ATCC). BEAS-2B cells were cultured according to instructions provided by ATCC using BEGM (bronchial epithelial growth media) purchased from Clonetics Corp. HELA cell cultures, used for detection and titration of virus, were maintained in Eagle's minimum essential media containing 10% fetal calf serum, 2mM I-glutamine, and 10 mM HEPES buffer (MEM).
A modification of the method reported by Subauste et al., Supra, for in vitro infection of human bronchial epithelial cells with rhinovirus was used in these studies. BEAS-2B cells (2x10°/well) were cultured in collagen-coated wells for 24 hours prior to infection with rhinovirus. Rhinovirus serotype 39 was added to cell cultures for one hour incubation at 34°C after which inoculum was replaced with fresh media and cultures were incubated for an additional 72 hours at 34°C. :
Supernatants collected at 72 hours post-infection were assayed for cytokine protein concentration by ELISA using commercially available kits (R&D Systems). Virus yield was also determined from culture supernatants using a microtitration assay in
HELA cell cultures (Subauste et al., supra 1995). In cultures treated with p38 kinase inhibitors, drug was added 30 minutes prior to infection. Stocks of compounds were prepared in DMSO (10 mM drug) and stored at -20°C.
For detection of p38 kinase, cultures were incubated in basal media without growth factors and additives to reduce endogenous levels of activated p38 kinase.
Cells were harvested at various timepoints after addition of rhinovirus. Detection of tyrosine phosphorylated p38 kinase by immunoblot was analyzed by a commercially available kit and was performed according to the manufacturer's instructions (PhosphoPlus p38 MAPK Antibody Kit: New England BioLabs Inc.).
In some experiments, BEAS-2B cells were infected with influenza virus (strain A/PR/8/34) in place of rhinovirus. Culture supernatant was harvested 48 and 72 hour post-infection and tested by ELISA for cytokine as described above.
Cells and Virus: Influenza A/PR/8/34 sub type HIN1 (VR-95 American Type
Culture Collection, Rockville, MD) was grown in the allantoic cavity of 10 day old chicken eggs. Following incubation at 37°C, and refrigeration for 2 1/2 hours at 4°C, allantoic fluid was harvested, pooled, and centrifuged (1,000 rcf, 15 min; 4°C) to remove cells. Supernatent was aliquoted and stored at -70°C. The titer of the stock culture of virus was 1.0 x 10'° Tissue Culture Infective Dose/ml (TCIDsp)
Inoculation procedure: Four-six week old female Balb/cAnNcrIBr mice were obtained from Charles River, Raleigh, NC. Animals were infected intranasally.
Mice were anesthetized by intraperitioneal injection of Ketamine (40mg/kg; Fort
Dodge Labs, Fort Dodge, 1a) and Xylazine (5 mg/kg, Miles, Shawnee Mission, Ks) and then inoculated with 100 TCID50 of PRS diluted in PBS in 20 ul. Animals were observed daily for signs of infection. All animal studies were approved by
SmithKline Beecham Pharmaceuticals Institutional Animal Care and Use
Committee.
Virus titration: At various times post infection, animals were sacrificed and lungs were aseptically harvested. Tissues were homogenized, in vials containing 1 micron glass beads (Biospec Products, Bartlesville, OK) and 1 ml. of Eagles minimal essential medium. Cell debris was cleared by centrifugation at 1,000 rcf for 15 minutes at 4°C, and supernatants were serially diluted on Madin-Darby canine kidney (MDCK) cells. After 5 days of incubation at 37°C (5% CO), 50 pul of 0.5%
Yoru a WO 01/19322 PCT/US00/25386 . chick red blood cells were added per well, and agglutination was read after 1 hour at room temperature. The virus titer is expressed as 50% tissue culture infective dose (TCIDsp) calculated by logistic regression. ) ELISA: Cytokine levels were measured by quantitative ELISA using commercially available kits. Ear samples were homogenized using a tissue minser in PBS. Cell debris was cleared by centrifugation at 14,000 rpm for 5 minutes. The cytokine concentrations and thresholds were determined as described by the manufacturer;
IL-6, IFN-y, and KC (R&D Systems, Minneapolis, MN).
Myeloperoxidase Assay: Myeloperoxidase (MPO) activity was determined kinetically as described by Bradley et al. (1982). Briefly, rabbit cornea were homogenized in
Hexadecyl Trimethyl-Ammonium Bromide (HTAB) (Sigma Chemical Co. St. Louis,
Mo) which was dissolved in 0.5 m Potassium phosphate buffer (J.T. Baker Scientific,
Phillipsburg, NJ). Following homogenization, the samples were subjected to freeze- thaw-sonication (Cole-Parmer 8853, Cole-Parmer, Vernon Hills, II) 3 times.
Suspensions were then cleared by centrifugation at 12,500 x g for 15 minutes at 4°C.
MPO enzymatic activity was determined by colormetric change in absorbance during a reaction of O-Dianisidine dihydrochloride (ODI) 0.175 mg/ml (Sigma Chemical Co.
St. Louis, Mo) with .0002% Hydrogen peroxide (Sigma Chemical Co. St. Louis, Mo).
Measurements were performed by using a Beckman Du 640 Spectrophotometer (Fullerton, Ca.) fitted with a temperature control device. 50 ul of material to be assayed was added to 950 ul of ODI and change in absorbance was measured at a wave length of 460 nm for 2 minutes at 25°C.
Whole Body Plethysomography: Influenza virus infected mice were placed into a whole body plethysomograph box with an internal volume of approximately 350-ml.
A bias airflow of one /min was applied to the box and flow changes were measured and recorded with a Buxco XA data acquisition and respiratory analysis system (Buxco Electronics, Sharon, CT). Animals were allowed to acclimate to the plethysmograph box for 2 min. before airflow data was recorded. Airway measurements were calculated as Penh (enhanced pause). Penh has previously been shown as an index of airway obstruction and correlates with increased intrapleural pressure. The algorithm for Penh calculation is as follows: Penh = [(expiratory time / relaxation time)-1] x (peak expiratory flow / peak inspiratory flow) where relaxation time is the amount of time required for 70% of the tidal volume to be expired.
Determination of arterial oxygen saturation. A Nonin veterinary hand held pulse oximeter 8500V with lingual sensor (Nonin Medical, Inc., Plymouth MN) was used to determine daily arterial oxygen saturation %SpO2 as described (Sidwell et al. 1992 Antimicrobial Agents and Chemotherapy 36:473-476). .
Results:
Inhibition of cytokine production by specific inhibitors of p38 MAP kinase:
Consistent with published reports, IL-6, IL-8, and GM-CSF were detected 72 hours post-infection of BEAS-2B cells with rhinovirus-39 (multiplicity of infection; MOI 1.0) (figure 1). Production of IL-6, IL-8, and GM-CSF was not mediated through
IL-1 or TNF produced in response to rhinovirus infection since addition of neutralizing antibodies to IL-1 and TNF to the infected cultures did not reduce the amount of IL-6, IL-8 or GM-CSF produced (not shown). Productive infection of cells was confirmed by titering infectious supernatants from BEAS-2B cells on
HELA monolayers. There was low but consistent replication of virus during the 72 hour culture period resulting in 1.22 + 0.3 log TCID5 increase over the initial input inoculum (n=6 experiments). To investigate the role of p38 kinase signal transduction in rhinovirus-induced cytokine production by epithelial cells, specific p38 kinase inhibitors SB203580, Compound II, Compound III, and an inactive analog, SKF106978, were tested for their ability to inhibit cytokine production in rhinovirus-infected BEAS-2B cell cultures. The compound (4-Fluorophenyl)-2-(4- methylsulfinylphenyl)-5-(4-pyridyl)-imidazole is alternatively referred to as SB 203580 and may be found in US patent 5,656,644. The compound zrans-1-(4-
Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4-yljimidazole also known as Compound II may be found in WO 97/25048. The compound 4-(4-
Fluorophenyl-5-[(2-phenylamino)pyrimidin-4-yl]- 1-(piperdin-4-yl)imidazole, also known as Compound III may be found in US Patent 5,658,903. The compound 2- (4-Methylsulfinyl)-3-[4-(2-methylpyridyl]-6,7-dihydro[ 5SH]pyrrolo[ 1,2-alimidazole, is also known as SB 106978. Concentrations of IL-8, IL-6 and GM-CSF in culture supernatants from infected cells treated with inhibitors were all lower than those from untreated infected cultures (figure 2). IL-6 was the most sensitive to inhibition with significant inhibition (40%) being observed with SB 203580 concentrations as low as 30 nM. GM-CSF was the least sensitive to inhibition by SB 203580, with an
ICs of approximately 4 uM.
Another inhibitor of p38 kinase, Compound II, was slightly more potent in inhibiting GM-CSF with an ICs of approximately 1 uM. Compound Hl was comparable to SB 203580 in inhibiting IL-6 and IL-8 production. As expected based on the relative potency of these compounds in specific binding to p38 kinase (data shown in legend box), cytokine inhibition was greatest with Compound III,
I WO 01/19322 PCT/US00/25386 with an IC50 value < 10 nM for IL-6, while SKF106978 was inactive at all . concentrations tested. Maximum effect obtained by any of the p38 kinase inhibitors against any of the three cytokines was 50%% -70% inhibition. The inhibition of cytokine production by CSAIDs was not due to general cell cytotoxicity as determined by standard XTT assays (CCsg > 40 uM for all compounds tested) (Roehm et al., J. of Immunol. Methods 142:257-265 (1991).
These compounds also did not exhibit direct antiviral activity as assessed using a standard HELA cell antiviral assay (MICsq > 10 uM for all compounds tested) (Andries et al, Journal of Virology 64(3):1117-1123 (1990) or by measuring virus yield in the RV-infected BEAS-2B cultures directly (not shown).
Activation of p38 kinase by rhinovirus infection:
The presence of tyrosine phosphorylated p38 kinase was measured by immunoblot at various times after the addition of virus to BEAS-2B cultures. Rhinovirus infection of
BEAS-2B cells resulted in an increase in phosphorylated p38 kinase that was both dose and time-dependent. Increases in phosphorylated p38 kinase were evident by 15 minutes post exposure to rhinovirus-39 (MOI 10), appeared to peak by 30 minutes after addition of virus and remained elevated 60 minutes post-infection (figure 3). In addition, rhinovirus-induced tyrosine phosphorylation of p38 kinase was dose- dependent (figure 4). When cells were cultured in the absence of virus, there was no increase in the amount of tyrosine phosphorylation of p38 kinase at any of the timepoints tested. Overall levels of p38 kinase protein were comparable between all the groups indicating that virus infection caused phosphorylation of p38 kinase without de novo synthesis of protein (figures 3 and 4).
Effects on in vitro influenza virus infection:
Exposure of BEAS-2B cells with influenza virus (A/PR/8/34; MOI 1.0) also resulted in elaboration of IL-8 and IL-6 as measured 48 - 72 hours post-infection, although the secreted protein levels were lower than that obtained with rhinovirus infection.
Consistent with observations in rhinovirus-infected cells, treatment of influenza infected-BEAS-2B cells with p38 kinase inhibitors, Compound IV, 1-(4-
Piperidinyl)-4-(4-fluorophenyl)-5-[(2-methylphenyl)amino]pyrimidin-4- yllimidazole and Compound II, 1-trans-4-hydroxycyclohexyl)-4-(4-fluorophenyl)- 5-[(2-methoxy)pyrimidin-4-yllimidazole, was also effective in inhibiting IL-6 and
IL-8 production.
Effects on in vivo influenza virus infection:
Five (5) independent and reproducible studies demonstrated the efficacy of . therapeutic dosing with Compound V, 1-(4-Piperidiny1)-4-(4-fluorophenyl)-5-(2- methoxy-4-pyrimidinyl)imidazole and Compound VI, 1-(1,3-Dihydroxyprop-2-yl)- 4-(4-fluorophenyl)-5-[2-phenoxypyrimidin-4-yl]Jimidazole at improving clinical disease in the murine influenza pneumonia model. BALB/c mice were dosed orally b.i.d. on days 3-8 post influenza A/PR8 and monitored daily for weight loss, pulmonary functions and arterial blood oxygen levels %Sp05. The antiviral Tamiflu was used as control and demonstrated 47% improvement in pulmonary functions : 10 (p<0.0l days 5-12), 64% improved %Sp02 (p<0.01 days 5-18), and prevention of weight loss relative to placebo. The optimal dose of Compound VI was 10 mg/kg leading to 39% improvement in pulmonary functions (p<0.01 days 5-12), 30% improvement in %Sp0; (p<0.01 days 5-13, p<0.05 days 14-15), and a similar effect on weight loss as Tamiflu treatment. Efficacy was observed in doses as low as 1 mg/kg: 27% improvement in pulmonary functions (p<0.01 days 6-9), 11.6% (p<0.01
Days 7-13). At 0.1 mg/kg, we observed 19% improvement in pulmonary functions (p<0.05 day 7,8) but no effect on %Sp0, or weight loss. At 10 mg/kg, Compound
VI was equally effective to Compound V at 30 mg/kg. Samples were collected for evaluation of virus titers and cytokines in lung homogenates. A non-significant trend for inhibition of lung cytokines IL-6, KC, IFN-gamma, and RANTES was observed. There was no negative effect on lung virus titers.
No negative effect on immunity to secondary influenza virus infection: In two studies, mice treated with Compound VI or Compound V during acute PR/8 (HIN1) influenza infection were protected from a lethal challenge with the same virus as demonstrated by 100% survival and normal pulmonary functions. All control primary infection animals died by Day 7. Thus, the CSAIDS have no effect on immunity to a homologous challenge.
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without oe WO 01/19322 PCT/US00/25386 further elaboration, it is believed that one skilled in the art can, using the preceding . description, utilize the present invention to its fullest extent. Therefore the
Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.
Claims (52)
- What is Claimed Is:I. A CBSP/p38 inhibitor for use in treating the common cold or respiratory viral infection caused by human rhinovirus (HRV), other enteroviruses, coronavirus, influenza, virus, parainfluenza virus, respiratory syncytial virus, or adenovirus in a human, wherein the said inhibitor is administered to said human.
- 2. The CBSP/p38 inhibitor according to Claim 1 wherein the respiratory viral infection exacerbates asthma.
- 3. The CBSP/p38 inhibitor according to Claim 1 wherein the respiratory viral infection exacerbates chronic bronchitis.
- 4. The CBSP/p38 inhibitor according to Claim 1 wherein the respiratory viral infection exacerbates chronic obstructive pulmonary disease.
- S. The CBSP/p38 inhibitor according to Claim i wherein the respiratory viral infection exacerbates otitis media.
- 6. The CBSP/p38 inhibitor according to Claim 1 wherein the respiratory viral infection exacerbates sinusitis.
- 7. The CBSP/p38 inhibitor according to Claim 1 wherein the respiratory viral infection is associated with a secondary bacterial infection, such as otitis media, sinusitis, or pneumonia.
- 8. The CBSP/p38 inhibitor according to any one of Claims 1 to 7 wherein said CSBP/p38 inhibitor is administered with a second therapeutic agent.
- 9. The CBSP/p38 inhibitor according to Claim 8 wherein the second therapeutic agentis an antiviral agent selected from ribavirin, amantidine, rimantidine, Pleconaril, AG 7088 or BTA- 188; an antihistamine; a decongestant; a steroid; an antibiotic; an anti-inflammatory agent selected from an NSAID, a COX-1 or COX-2 inhibitor, ASA, or indomethacin, an influenza neuraminidase inhibitor selected from zamanivar (Relenza), oseltamivir (Tamiflu) or RWJ-270201.
- 10. The CBSP/p38 inhibitor according to any one of Claims 1 to 7 wherein the -10- AMENDED SHEET i therapeutic agent is administered orally, topically (intranasal) or via inhalation (aerosol), or both topically and via inhalation.
- 11. The CBSP/p38 inhibitor according to Claim 10 wherein said CSBP/p38 inhibitor is administered with a second therapeutic agent.
- 12. The CBSP/p38 inhibitor according to Claim 11 wherein the second therapeutic agent may be administered by a different route than the CSBP/p38 inhibitor.
- 13. The CBSP/p38 inhibitor according to Claim 12 wherein the second therapeutic agent is an antiviral agent ribavirin, amantidine, nmantidine, Pleconaril, AG 7088, BTA-188; an antihistamine; a decongestant; a steroid; an antibiotic; an anti inflammatory agent selected from an NSAID, a COX-1 or COX-2 inhibitor, ASA, or indomethacin; or an influenza neuraminidase inhibitor selected from zamanivar (Relenza), oseltamivir(Tamiflu) or RWJ-270201.
- 14. The CBSP/p38 inhibitor according to Claim 1 wherein the CSBP/p38 inhibitor is selected from a compound disclosed in US Patent 5,716,972, US 5,686,455, US 5,656,644, US 5,593,992, US 5,593,991, US 5,663,334, US 5,670,527, US 5,559,137, US 5,658,903, US 5,739,143, US 5,756,499, US 5,716,955, WO 98/25619, WO 97/25048, WO 99/01452, WO 97/25047, WO 99/01131, WO 99/01130, WO 97/33883, WO 97/35856, WO 97/35855, WO 98/06715, WO 98/07425, WO 98/28292, WO 98/56377, WO 98/07966, WO 99/01136, WO 99/17776, WO 99/01131. WO 99/01130, WO 99/32121, WO 00/26209, WO 99/58502, WO 99/58523, WO 99/57101, WO 99/61426, WO 99/59960, WO 99/59959, WO 00/18738, WO 00/17175, WO 99/17204, WO 00/20402, WO 99/64400, WO 00/01688, WO 00/07980, WO 00/07991, WO 00/06563, WO 00/12074, WO 00/12497, WO 00/31072, WO 00/31063, WO 00/23072, WO 00/31065, WO 00/35911, WO 00/39116, WO 00/43384, WO 00/41698, WO 97/36587, WO 97/47618, WO 97/16442, WO 97/16441, WO 97/12876, WO 98/7966, WO 98/56377, WO 98/22109, WO 98/24782, WO 98/24780, WO 98/22457, WO 98/52558, WO 98/52941, WO 98/5293 7, WO 98/52940, WO 98/56788, WO 98/27098 . WO 99/003 57, WO 98/47892, WO 98/47899, WO 99/03837, WO 99/01441, WO 99/01449, WO 99/03484, WO 95/09853, WO 95/09851, WO 95/09847, WO 95/09852, WO 92/12154, WO 94/19350, WO 99/15164, WO 98/50356, DE 19842833, or JP 2000 86657. -20- AMENDED SHEET
- 15. The CBSP/p38 inhibitor according to claim 1 or 14 wherein the compound is 1- (1,3- Dihydroxyprop-2-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4- yl)imidazole, or a pharmaceutically acceptable salt thereof.
- 16. The CBSP/p38 inhibitor according to claim 1 or 14 wherein the compound is trans- 1-(4Hydroxycyclohexyl)-4-(4-fluorophenyl)-5 -[(2-methoxy)pyrimidin-4- yl]imidazole; 1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinyl)imida.zole; or (4-Fluorophenyl)-2-(4-methylsulfmylphenyl)-5-(4- pyridyl)-irnidazole.
- 17. The CBSP/p38 inhibitor according to Claim 1 or 14 wherein the compound is VX-745, RW] 67657, RWJI-68354, ZM 336372, SU 4984 or RPR-200765A.
- 18. A CBSP/p38 inhibitor for use in treating the influenza induced pneumonia in a human in need thereof wherein the CBSP/p38 inhibitor is administered to said human.
- 19. The CBSP/p38 inhibitor according to Claims 18 wherein the CSBP/p38 inhibitor is administered with a second therapeutic agent.
- 20. The CBSP/p38 inhibitor according to Claim 19 wherein the second therapeutic agent is an antiviral agent ribavirin, amantidine, rimantidine, Pleconaril, AG 7088, BTA-188; an antihistamine, a decongestant; a steroid; an antibiotic; an anti- inflammatory agent selected from an NSAID, a COX-1 or COX-2 inhibitor, ASA, or indomethacin; or an influenza neuraminidase inhibitor selected from zamanivar (Relenza), oseltamivir (Tainiulu) or RWJ-270201.
- 21. The CBSP/p38 inhibitor according to Claim 18 wherein the therapeutic agent is administered orally, topically (intranasal) or via inhalation (aerosol), or both topically and via inhalation.
- 22. The CBSP/p38 inhibitor according to Claim 21 wherein a second therapeutic agent may be administered by a different route than the CSBP/p38 inhibitor.
- 23. The CBSP/p38 inhibitor according to any one of Claims 18 to 22 wherein the CSBP/p38 inhibitor is selected from a compound disclosed in US Patent 5,716,972, US 5,686,455, US 5,656,644, US 5,593,992, US 5,593,991, US 5,663,334, US 5,670,527, US 5,559,137, 5,658,903, US 5,739,143, US 5,756,499, -21- AMENDED SHEETUS 5,716,955, WO 98/25619, WO 97/25048, WO 99/01452, WO 97/25047, WO 95/01131, WO 99/01130, WO 97/33883, WO 97/35856, WO 97/35855, WO 98/06715, WO 98/07425, WO 98/28292, WO 98/56377, WO 98/07966, WO 99/01136, WO 99/17776, WO 99/01131, WO 99/01130, WO 99/32121, WO 00/26209, WO 99/58502, WO 99/58523, WO 99/57101, WO 99/61426, WO 99/59960, WO 99/59959, WO 00/18738, WO 00/17175, WO 99/17204, WO 00/20402, WO 99/64400, WO 00/01688, WO 00/07980, WO 00/07991, WO 00/06563, WO 00/12074, WO 00/12497, WO 00/31072, WO 00/31063, WO 00723072, WO 00/31065, WO 00/39116, WO 00/43384, WO 00/41698, WO 97/36587, WO 97/47618, WO 97/16442, WO 97/16441, WO 97/12876, WO 98/7966, WO 98/56377, WO 98/22109, WO 98/24782, WO 98/24780, WO 98/22457, WO 98/52558, WO 98/52941, WO 98/52937, WO 98/52940, WO 98/56788, WO 98/27098, WO 99/00357, WO 98/47892, WO 98/47899, WO 99/03837, WO 99/01441, WO 99/01449, WO 99/03484, WO 95/09853, WO 95/09851, WO 95/09847, WO 95/09852, WO 92/12154, WO 94/19350, WO 99/15164, WO 98/50356, DE 19842833, or JP 200086657.
- 24. The CBSP/p38 inhibitor according to claim 18 wherein the compound is 1-(1,3- Dihydroxyprop-2-y1)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl)imidazole, or a pharmaceutically acceptable salt thereof.
- 25. The CBSP/p38 inhibitor according to claim 18 wherein the compound is trans-1- (4Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4- yljimidazole;1-(4-Piperidiny1)-4-(4-fluorophenyl)-5 -(2-methoxy-4- pyrimidinyl)imidazole; or (4-Fluorophenyl)-2-(4-methylsulfmylphenyl)-5(4- pyridyl)-imidazole.
- 26. Use of a CBSP/p38 inhibitor in treating the common cold or respiratory viral infection caused by human rhinovirus (HRV), other enteroviruses, coronavirus, influenza, virus, parainfluenza virus, respiratory syncytial virus, or adenovirus in a human, wherein the said inhibitor is administered to said human.
- 27. Use according to Claim 1 wherein the respiratory viral infection exacerbates asthma.
- 28. Use according to Claim 1 wherein the respiratory viral infection exacerbates chronic bronchitis.22. AMENDED SHEET
- 29. Use according to Claim 1 wherein the respiratory viral infection exacerbates chronic obstructive pulmonary disease.
- 30. Use according to Claim 1 wherein the respiratory viral infection exacerbates otitis media.
- 31. Use according to Claim 1 wherein the respiratory viral infection exacerbates sinusitis.
- 32. Use according to Claim 1 wherein the respiratory viral infection is associated with a secondary bacterial infection, such as otitis media, sinusitis, or pneumonia.
- 33. Use according to any one of Claims 1 to 7 wherein said CSBP/p38 inhibitor is administered with a second therapeutic agent.
- 34. Use according to Claim 8 wherein the second therapeutic agent is an antiviral agent selected from ribavirin, amantidine, rimantidine, Pleconaril, AG 7088 or BTA- 188; an antihistamine; a decongestant; a steroid; an antibiotic; an anti- inflammatory agent selected from an NSAID, a COX-1 or COX-2 inhibitor, ASA, or indomethacin, an influenza neuraminidase inhibitor selected from zamanivar (Relenza), oseltamivir (Tamiflu) or RWJ-270201.
- 35. Use according to any one of Claims 1 to 7 wherein the therapeutic agent is administered orally, topically (intranasal) or via inhalation (aerosol), or both topically and via inhalation.
- 36. Use according to Claim 10 wherein said CSBP/p38 inhibitor is administered with a second therapeutic agent.
- 37. Use according to Claim 11 wherein the second therapeutic agent may be administered by a different route than the CSBP/p38 inhibitor.
- 38. Use according to Claim 12 wherein the second therapeutic agent is an antiviral agent ribavirin, amantidine, nmantidine, Pleconaril, AG 7088, BTA-188; an antihistamine; a decongestant; a steroid; an antibiotic; an anti inflammatory agent selected from an NSAID, a COX-l or COX-2 inhibitor, ASA, or 23- AMENDED S-2ET indomethacin; or an influenza neuraminidase inhibitor selected from zamanivar (Relenza), oseltamivir(Tamiflu) or RWJ-270201.
- 39. Use according to Claim 1 wherein the CSBP/p38 inhibitor is selected from a compound disclosed in US Patent 5,716,972, US 5,686,455, US 5,656,644, US 5,593,992, US 5,593,991, US 5,663,334, US 5,670,527, US 5,559,137, US 3,658,903, US 5,739,143, US 5,756,499, US 5,716,955, WO 98/25619, WO 97/25048, WO 99/01452, WO 97/25047, WO 99/01131, WO 99/01130, WO 97/33883, WO 97/35856, WO 97/35855, WO 98/06715, WO 98/07425, WO 98/28292, WO 98/56377, WO 98/07966, WO 99/01136, WO 99/17776, WO 99/01131. WO 99/01130, WO 99/32121, WO 00/26209, WO 99/58502, WO 99/58523, WO 99/57101, WO 99/61426, WO 99/59960, WO 99/59959, WO 00/18738, WO 00/17175, WO 99/17204, WO 00/20402, WO 99/64400, WO 00/01688, WO 00/07980, WO 00/07991, WO 00/06563, WO 00/12074, WO 00/12497, WO 00/31072, WO 00/31063, WO 00/23072, WO 00/31065, WO 00/35911, WO 00/39116, WO 00/43384, WO 00/41698, WO 97/36587, WO 97/47618, WO 97/16442, WO 97/16441, WO 97/12876, WO 98/7966, WO 98/56377, WO 98/22109, WO 98/24782, WO 98/24780, WO 98/22457, WO 98/52558, WO 98/52941, WO 98/5293 7, WO 98/52940, WO 98/56788, WO 98/27098 . WO 99/003 57, WO 98/47892, WO 98/47899, WO 99/03837, WO 99/01441, WO 99/01449, WO 99/03484, WO 95/09853, WO 95/09851, WO 95/09847, WO 95/09852, WO 92/12154, WO 94/19350, WO 99/15164, WO 98/50356, DE 19842833, or JP 2000 86657.
- 40. Use according to claim 1 or 14 wherein the compound is 1-(1,3- Dihydroxyprop- 2-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-y1)imidazole, or a pharmaceutically acceptable salt thereof.
- 41. Use according to claim 1 or 14 wherein the compound is trans-1-(4- Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4- yl]imidazole; 1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinyl)imida.zole; or (4-Fluorophenyl)-2-(4-methylsulfmylphenyl)-5-(4- pyridyl)-imidazole.
- 42. Use according to Claim 1 or 14 wherein the compound is VX-745, RW] 67657, RWJ-68354, ZM 336372, SU 4984 or RPR-200765A.
- 43. Use of CBSP/p38 inhibitor in treating the influenza induced pneumonia in a224. AMENDED SHEET human in need thereof wherein the CBSP/p38 inhibitor is administered to said human.
- 44. Use according to Claims 18 wherein the CSBP/p3 8 inhibitor is administered with a second therapeutic agent.
- 45. Use according to Claim 19 wherein the second therapeutic agent is an antiviral agent ribavirin, amantidine, rimantidine, Pleconaril, AG 7088, BTA-188; an antihistamine, a decongestant; a steroid; an antibiotic; an anti-inflammatory agent selected from an NSAID, a COX-1 or COX-2 inhibitor, ASA, or indomethacin; or an influenza neuraminidase inhibitor selected from zamanivar (Relenza), oseltamivir (Tainiulu) or RWJ-270201.
- 46. Use according to Claim 18 wherein the therapeutic agent is administered orally, topically (intranasal) or via inhalation (aerosol), or both topically and via inhalation.
- 47. Use according to Claim 21 wherein a second therapeutic agent may be administered by a different route than the CSBP/p38 inhibitor.
- 48. Use according to any one of Claims 18 to 22 wherein the CSBP/p38 inhibitor is selected from a compound disclosed in US Patent 5,716,972, US 5,686,455, US 5,656,644, US 5,593,992, US 5,593,991, US 5,663,334, US 5,670,527, US 5,559,137, US 5,658,903, US 5,739,143, US 5,756,499, US 5,716,955, WO 98/25619, WO 97/25048, WO 99/01452, WO 97/25047, WO 99/01131, WO 99/01130, WO 97/33883, WO 97/35856, WO 97/35855, WO 98/06715, WO 98/07425, WO 98/28292, WO 98/56377, WO 98/07966, WO 99/01136, WO 99/17776, WO 99/01131, WO 99/01130, WO 99/32121, WO 00/26209, WO 99/58502, WO 99/58523, WO 99/57101, WO 99/61426, WO 99/59960, WO 99/59959, WO 00/18738, WO 00/17175, WO 99/17204, WO 00/20402, WO 99/64400, WO 00/01688, WO 00/07980, WO 00/07991, WO 00/06563, WO 00/12074, WO 00/12497, WO 00/31072, WO 00/31063, WO 00/23072, WO 00/31065, WO 00/39116, WO 00/43384, WO 00/41698, WO 97/36587, WO 97/47618, WO 97/16442, WO 97/16441, WO 97/12876, WO 98/7966, WO 98/56377, WO 98/22109, WO 98/24782, WO 98/24780, WO 98/22457, WO 98/52558, WO 98/52941, WO 98/52937, WO 98/52940, WO 98/56788, WO 98/27098, WO 99/00357, WO 98/47892, WO 98/47899, WO 99/03837, WO -25- AMENDED SHEET99/01441, WO 99/01449, WO 99/03484, WO 95/09853, WO 95/09851, WO 95/09847, WO 95/09852, WO 92/12154, WO 94/19350, WO 99/15164, WO 98/50356, DE 19842833, or JP 200086657. :
- 49. Use according to claim 18 wherein the compound is 1-(1,3Dihydroxyprop-2-y1)- 4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl)imidazole, or a pharmaceutically acceptable salt thereof.
- 50. Use according to claim 18 wherein the compound is trans-1-(4- Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4- yljimidazole; 1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinyl)imidazole; or (4-Fluorophenyl)-2-(4-methylsulfmylphenyl)-5(4- pyridyl)-imidazole.
- 51. A CBSP/p38 inhibitor according to claim 1 or 18, substantially as herein described and exemplified and/or described with reference to the accompanying figures.
- 52. Use according to claim 26 or 43 substantially as herein described and exemplified and/or described with reference to the accompanying figures. -26- AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15449499P | 1999-09-17 | 1999-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200202060B true ZA200202060B (en) | 2003-05-28 |
Family
ID=22551566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200202060A ZA200202060B (en) | 1999-09-17 | 2002-03-13 | Use of CSAIDS in rhinovirus infection. |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1223924A4 (en) |
JP (1) | JP2003516314A (en) |
KR (1) | KR20020032591A (en) |
CN (1) | CN1382044A (en) |
AR (1) | AR025691A1 (en) |
AU (1) | AU7584500A (en) |
BR (1) | BR0014041A (en) |
CA (1) | CA2385722A1 (en) |
CO (1) | CO5200855A1 (en) |
CZ (1) | CZ2002939A3 (en) |
HU (1) | HUP0204333A3 (en) |
IL (1) | IL148329A0 (en) |
NO (1) | NO20021301L (en) |
PL (1) | PL363116A1 (en) |
TR (1) | TR200200673T2 (en) |
WO (1) | WO2001019322A2 (en) |
ZA (1) | ZA200202060B (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
EP1337255A4 (en) * | 2000-10-19 | 2006-01-25 | Smithkline Beecham Corp | Use of p38 inhibitors for the treatment of inflammation-enhanced cough |
JP4524072B2 (en) | 2000-10-23 | 2010-08-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | New compounds |
CA2479737C (en) * | 2002-03-20 | 2011-05-24 | Elan Pharma International Ltd. | Nanoparticulate compositions of map kinase inhibitors |
RU2004132847A (en) * | 2002-04-05 | 2006-08-20 | Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De) | METHOD FOR TREATING HYPERSECRATION OF SLIMAS |
CA2492033A1 (en) * | 2002-07-09 | 2004-01-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
JP4593953B2 (en) * | 2004-03-30 | 2010-12-08 | 杏林製薬株式会社 | Rhinovirus infection prophylaxis |
JP2008509143A (en) * | 2004-08-04 | 2008-03-27 | シェーリング コーポレイション | Pharmaceutical formulations containing pleconaril for the treatment of airway diseases |
AR053346A1 (en) | 2005-03-25 | 2007-05-02 | Glaxo Group Ltd | COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38 |
EP2276505B1 (en) | 2008-03-20 | 2013-09-18 | TANO, Krister | Nasal spray or nasal drops for treatment of common cold |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
WO2011035128A1 (en) * | 2009-09-17 | 2011-03-24 | Mutual Pharmaceutical Company, Inc. | Method of treating asthma with antiviral agents |
GB201010193D0 (en) * | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
GB201010196D0 (en) * | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
US11730760B2 (en) | 2011-04-01 | 2023-08-22 | The Bioregentech Institute, Inc. | Laser assisted wound healing protocol and system |
US11389663B2 (en) | 2011-04-01 | 2022-07-19 | Bioregentech, Inc. | Laser assisted wound healing protocol and system |
GB201611712D0 (en) | 2016-07-02 | 2016-08-17 | Hvivo Services Ltd | Methods and compounds for the treatment or prevention of severe or persistent influenza |
US11479770B2 (en) | 2017-10-05 | 2022-10-25 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of DUX4 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
GB201721793D0 (en) * | 2017-12-22 | 2018-02-07 | Hvivo Services Ltd | Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza |
WO2021216754A1 (en) * | 2020-04-21 | 2021-10-28 | Spring Discovery, Inc. | Use of p38 mapk inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3984396A (en) * | 1971-06-01 | 1976-10-05 | Icn Pharmaceuticals, Inc. | 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters |
US3927216A (en) * | 1971-06-01 | 1975-12-16 | Icn Pharmaceuticals | 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections |
US5656644A (en) * | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
IL118544A (en) * | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | Imidazole derivatives, process for their preparation and pharmaceutical compositions comprising them |
AP9700912A0 (en) * | 1996-01-11 | 1997-01-31 | Smithkline Beecham Corp | Novel cycloalkyl substituted imidazoles |
WO2000040243A1 (en) * | 1999-01-08 | 2000-07-13 | Smithkline Beecham Corporation | Novel compounds |
-
2000
- 2000-09-15 AU AU75845/00A patent/AU7584500A/en not_active Abandoned
- 2000-09-15 CN CN00813012A patent/CN1382044A/en active Pending
- 2000-09-15 PL PL00363116A patent/PL363116A1/en not_active Application Discontinuation
- 2000-09-15 EP EP00965060A patent/EP1223924A4/en not_active Withdrawn
- 2000-09-15 CZ CZ2002939A patent/CZ2002939A3/en unknown
- 2000-09-15 WO PCT/US2000/025386 patent/WO2001019322A2/en not_active Application Discontinuation
- 2000-09-15 KR KR1020027003518A patent/KR20020032591A/en not_active Application Discontinuation
- 2000-09-15 HU HU0204333A patent/HUP0204333A3/en unknown
- 2000-09-15 BR BR0014041-4A patent/BR0014041A/en not_active IP Right Cessation
- 2000-09-15 JP JP2001522960A patent/JP2003516314A/en not_active Withdrawn
- 2000-09-15 TR TR2002/00673T patent/TR200200673T2/en unknown
- 2000-09-15 CO CO00070099A patent/CO5200855A1/en not_active Application Discontinuation
- 2000-09-15 CA CA002385722A patent/CA2385722A1/en not_active Abandoned
- 2000-09-15 IL IL14832900A patent/IL148329A0/en unknown
- 2000-09-17 AR ARP000104866A patent/AR025691A1/en not_active Application Discontinuation
-
2002
- 2002-03-13 ZA ZA200202060A patent/ZA200202060B/en unknown
- 2002-03-15 NO NO20021301A patent/NO20021301L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1223924A2 (en) | 2002-07-24 |
JP2003516314A (en) | 2003-05-13 |
PL363116A1 (en) | 2004-11-15 |
KR20020032591A (en) | 2002-05-03 |
NO20021301L (en) | 2002-05-16 |
NO20021301D0 (en) | 2002-03-15 |
WO2001019322A3 (en) | 2001-10-04 |
AU7584500A (en) | 2001-04-17 |
CN1382044A (en) | 2002-11-27 |
CZ2002939A3 (en) | 2002-11-13 |
CA2385722A1 (en) | 2001-03-22 |
HUP0204333A3 (en) | 2004-07-28 |
IL148329A0 (en) | 2002-09-12 |
AR025691A1 (en) | 2002-12-11 |
EP1223924A4 (en) | 2004-07-14 |
HUP0204333A2 (en) | 2003-05-28 |
TR200200673T2 (en) | 2002-12-23 |
CO5200855A1 (en) | 2002-09-27 |
BR0014041A (en) | 2003-07-15 |
WO2001019322A2 (en) | 2001-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200202060B (en) | Use of CSAIDS in rhinovirus infection. | |
US11975012B2 (en) | Remdesivir treatment methods | |
JP6620324B2 (en) | Glutarimide derivatives, their use, pharmaceutical compositions based thereon and methods for producing glutarimide derivatives | |
US20130102607A1 (en) | Ureido-pyrazole derivatives for use in the treatment of rhinovirus infections | |
US7053098B1 (en) | 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors | |
EP1233950B1 (en) | 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS | |
JP2004530648A (en) | Use of p38 inhibitors for the treatment of inflammation-promoted cough | |
US20230210848A1 (en) | Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug | |
US9096585B2 (en) | Antiviral compounds and uses thereof | |
Chung et al. | A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus | |
US7053099B1 (en) | 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors | |
WO2022056115A1 (en) | Methods of treating symptoms of coronavirus infection | |
WO2013029006A1 (en) | Dengue virus and yellow fever virus therapies | |
WO2014146218A1 (en) | Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus | |
US6759410B1 (en) | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors | |
US11433080B2 (en) | Antiviral treatment | |
WO2023279031A1 (en) | Methods and compositions for treatment of covid-19 | |
JP2004511542A (en) | Use of p38 inhibitors for the treatment of smoke inhalation | |
WO2022092299A1 (en) | Therapeutic agent for covid-19 | |
US20040097473A1 (en) | Use of p38 inhibitors for the treatment of smoke inhalation | |
WO2014031571A1 (en) | Treatment of viral infections | |
US20040092532A1 (en) | Use of p38 inhibitors for the treatment of smoke inhalation | |
EP2747765A1 (en) | Compositions and methods for treating viral diseases |